Novavax/$NVAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novavax
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Ticker
$NVAX
Sector
Primary listing
Employees
952
Headquarters
Website
Novavax Metrics
BasicAdvanced
$1.2B
2.95
$2.54
2.50
-
Price and volume
Market cap
$1.2B
Beta
2.5
52-week high
$14.01
52-week low
$5.01
Average daily volume
7.8M
Financial strength
Current ratio
2.363
Quick ratio
2.155
Long term debt to equity
592.526
Total debt to equity
607.282
Interest coverage (TTM)
15.55%
Profitability
EBITDA (TTM)
407.506
Gross margin (TTM)
57.18%
Net profit margin (TTM)
39.20%
Operating margin (TTM)
33.96%
Effective tax rate (TTM)
1.98%
Revenue per employee (TTM)
$1,130,000
Management effectiveness
Return on assets (TTM)
14.52%
Return on equity (TTM)
-214.59%
Valuation
Price to earnings (TTM)
2.947
Price to revenue (TTM)
1.119
Price to book
32.32
Price to tangible book (TTM)
-16.14
Price to free cash flow (TTM)
-1.893
Free cash flow yield (TTM)
-52.82%
Free cash flow per share (TTM)
-3.961
Growth
Revenue change (TTM)
9.22%
Earnings per share change (TTM)
-211.46%
3-year revenue growth (CAGR)
-5.81%
10-year revenue growth (CAGR)
39.44%
3-year earnings per share growth (CAGR)
-49.15%
10-year earnings per share growth (CAGR)
-10.60%
What the Analysts think about Novavax
Analyst ratings (Buy, Hold, Sell) for Novavax stock.
Novavax Financial Performance
Revenues and expenses
Novavax Earnings Performance
Company profitability
Novavax News
AllArticlesVideos
Novavax beats quarterly revenue estimates on milestone payment
Reuters·3 weeks ago
Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study
Reuters·3 months ago
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
Reuters·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novavax stock?
Novavax (NVAX) has a market cap of $1.2B as of August 27, 2025.
What is the P/E ratio for Novavax stock?
The price to earnings (P/E) ratio for Novavax (NVAX) stock is 2.95 as of August 27, 2025.
Does Novavax stock pay dividends?
No, Novavax (NVAX) stock does not pay dividends to its shareholders as of August 27, 2025.
When is the next Novavax dividend payment date?
Novavax (NVAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Novavax?
Novavax (NVAX) has a beta rating of 2.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.